

November 14, 2016

To,  
General Manager,  
Bombay Stock Exchange Limited,  
P.J. Towers, Dalal Street, Fort,  
Mumbai: 400 001.

Respected Sir/Madam,

**Scrip code: 524500**

**Sub: OUTCOME OF THE BOARD MEETING HELD ON MONDAY, NOVEMBER 14, 2016.**

With the reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held on today, i.e. Monday, November 14, 2016, for which intimation was already given to you, the Board of Directors has:

- Taken on Record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016 along with the Limited Review Report as submitted by M/s. A.M. Ghelani & Co., Chartered Accountants, being the Statutory Auditors of the Company.
- Accepted the resignation tendered by Mr. Deepu Panankattil as the Director of the Company w.e.f November 30, 2016.


Further, the Board meeting commenced on 3.00 p.m. and concluded on 3.50 p.m.

Kindly find the same in order and acknowledge the receipt of the same.

Thanking You,

Yours faithfully,

For: KILITCH DRUGS (INDIA) LIMITED



**BHAVIN MEHTA  
EXECUTIVE DIRECTOR  
(DIN NO: 00147895)**



**AJIT M. GHELANI**  
**B.Com (Hons), F.C.A., GRAD. C.W.A.**

**CHINTAN A. GHELANI**  
**B.Com (Hons), F.C.A., C.S**

**INDEPENDENT AUDITORS' REVIEW REPORT**

To,  
The Board of Directors  
**Kilitch Drugs (India) Limited**

**LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER AND SIX MONTHS ENDED 30<sup>th</sup> SEPTEMBER, 2016**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** for the quarter and six months ended 30<sup>th</sup> September, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the Indian Accounting Standards and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A. M. Ghelani & Company**

Chartered Accountants

FRN: 103173W

  
**Chintan Ghelani**

Partner

Membership No.: 104391



Place : Mumbai

Dated : 14<sup>th</sup> November, 2016

**Enclosed: Unaudited financial results for the quarter and six months ended 30<sup>th</sup> September, 2016 of Kilitch Drugs (India) Limited**

# KILITCH DRUGS (INDIA) LIMITED

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED  
30TH SEPTEMBER 2016**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718


Rs. In Lacs

Sr. No.	Particulars	STANDALONE					
		Three Months Ended			Six Months Ended		Year Ended
		30/09/2016	30/06/2016	30/09/2015	30/09/2016	30/09/2015	31/03/2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
<b>1</b>	<b>Income from operations</b>						
	(a) Net Sales/Income from operations(net of Excise)	531.15	662.60	428.73	1193.75	824.47	2082.46
	(b) Other operating income	53.96	2.06	2.31	56.02	5.99	19.70
	<b>Total Income from Operations (Net)</b>	<b>585.11</b>	<b>664.66</b>	<b>431.05</b>	<b>1249.77</b>	<b>830.46</b>	<b>2102.16</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	313.75	314.60	103.26	628.35	401.61	891.84
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(19.68)	(9.59)	9.45	(29.25)	(3.79)	(18.61)
	(c) Employee Benefit Expenses	87.53	72.59	83.03	160.12	168.29	342.20
	(d) Depreciation and Amortisation Expenses	23.59	41.19	39.07	64.78	78.21	161.25
	(e) Export Product Registration Charges	4.88	36.84	30.90	41.72	45.55	149.28
	(f) Other Expenses	319.35	306.92	248.93	626.27	534.37	1098.66
	<b>Total Expenses</b>	<b>729.45</b>	<b>762.55</b>	<b>514.63</b>	<b>1492.00</b>	<b>1224.23</b>	<b>2824.62</b>
<b>3</b>	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(144.34)</b>	<b>(97.89)</b>	<b>(83.60)</b>	<b>(242.23)</b>	<b>(393.77)</b>	<b>(522.46)</b>
<b>4</b>	<b>Other Income</b>	<b>33.18</b>	<b>23.43</b>	<b>17.84</b>	<b>56.61</b>	<b>75.46</b>	<b>273.51</b>
<b>5</b>	<b>Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>(111.16)</b>	<b>(74.46)</b>	<b>(65.76)</b>	<b>(185.62)</b>	<b>(318.31)</b>	<b>(248.96)</b>
<b>6</b>	<b>Finance Costs</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>7</b>	<b>Profit / (Loss) from ordinary activities before exceptional items (5-6)</b>	<b>(111.16)</b>	<b>(74.46)</b>	<b>(65.76)</b>	<b>(185.62)</b>	<b>(318.31)</b>	<b>(248.96)</b>
<b>8</b>	<b>Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>9</b>	<b>Profit / (Loss) from ordinary activities before tax (7+8)</b>	<b>(111.16)</b>	<b>(74.46)</b>	<b>(65.76)</b>	<b>(185.62)</b>	<b>(318.31)</b>	<b>(248.96)</b>
<b>10</b>	<b>Tax Expenses</b>						
	Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred Tax	(21.10)	(3.26)	(15.67)	(24.36)	(19.19)	(43.61)
	Tax Adjustments of Earlier years	0.00	0.00	0.00	0.00	0.00	0.00
<b>11</b>	<b>Net Profit / (Loss) from ordinary activities after tax (9-10)</b>	<b>(90.06)</b>	<b>(71.20)</b>	<b>(60.08)</b>	<b>(161.26)</b>	<b>(299.12)</b>	<b>(205.35)</b>
<b>12</b>	<b>Extra Ordinary Items (net of tax expenses)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>13</b>	<b>Net Profit / (Loss) for the period (11+12)</b>	<b>(90.06)</b>	<b>(71.20)</b>	<b>(60.08)</b>	<b>(161.26)</b>	<b>(299.12)</b>	<b>(205.35)</b>
<b>14</b>	<b>Paid-Up equity share capital (Face Value Rs 10 per share)</b>	<b>1323.18</b>	<b>1323.18</b>	<b>1323.18</b>	<b>1323.18</b>	<b>1323.18</b>	<b>1323.18</b>
<b>15</b>	<b>Reserves excluding Revaluation Reserve [As per the latest Audited Balance Sheet]</b>						<b>10469.01</b>
<b>16.i</b>	<b>Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):</b>						
	(a) Basic	(0.68)	(0.54)	(0.38)	(1.22)	(2.26)	(1.55)
	(b) Diluted	(0.68)	(0.54)	(0.38)	(1.22)	(2.26)	(1.55)
<b>16.ii</b>	<b>Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):</b>						
	(a) Basic	(0.68)	(0.54)	(0.38)	(1.22)	(2.26)	(1.55)
	(b) Diluted	(0.68)	(0.54)	(0.38)	(1.22)	(2.26)	(1.55)

**Notes:**

- 1 The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 14th November, 2016.
- 2 The Company has operated only in one reportable segment i.e. Pharmaceuticals.
- 3 The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place: Mumbai  
Date: 14th November, 2016



For and on behalf of Board

*Bhavin Menta*  
BHAVIN MENTA  
Director



# KILITCH DRUGS (INDIA) LIMITED

## STATEMENT OF ASSETS AND LIABILITIES

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. (In Lacs)

Particulars	Standalone	
	As at 30th Sep, 2016	As at 31st March, 2016
	[Rs.]	[Rs.]
	(Unaudited)	(Audited)
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholders' Funds</b>		
Share capital	1,323.18	1,323.18
Reserves and surplus	10,307.75	10,469.01
<b>Current Liabilities</b>		
Short term Borrowings	50.64	8.92
Trade payables	503.25	362.95
Other current liabilities	293.30	328.82
Short-term provisions	85.26	76.79
<b>TOTAL</b>	<b>12,563.37</b>	<b>12,569.67</b>
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
Fixed assets		
Tangible assets	801.60	831.25
Intangible assets	2.51	2.81
Non-current investments	7,003.57	6,910.98
Deferred tax Assets (Net)	118.78	94.43
Long-term loans and advances	83.94	71.59
Other Non-current assets	-	-
<b>Current Assets</b>		
Current investments	2,178.33	2,312.07
Inventories	324.16	262.08
Trade receivables	1,642.14	1,636.55
Cash and Bank balances	232.36	251.86
Short-term loans and advances	175.99	194.53
Other Current assets	-	1.52
<b>TOTAL</b>	<b>12,563.37</b>	<b>12,569.67</b>

Place: Mumbai,

Dated: 14th November, 2016

For and on Behalf of the Board

*Bhavin Mehta*

**BHAVIN MEHTA**  
(Director)

